🟢 GRAIL is trading 4.2% up today amid optimism over FDA’s September 23 Galleri review

GRAIL is trading at $70.73, up 4.21%, as investors focus on the FDA’s scheduled September 23 advisory committee review of Galleri’s premarket approval application, announced August 7.

• The announcement previously sent shares up 5%, supporting the most likely explanation for the August 17 move.
• No new August 17 company announcement or broad-market catalyst was identified; major indexes were mixed, making company-specific regulatory optimism the stronger driver.